Added to YB: 2024-09-17
Pitch date: 2024-09-17
AADI [bullish]
Whitehawk Therapeutics, Inc.
+132.43%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments.
Market Cap
$194.7M
Pitch Price
$1.85
Price Target
5.70 (+33%)
Dividend
N/A
EV/EBITDA
-0.58
P/E
-2.36
EV/Sales
N/A
Sector
Biotechnology
Category
value
Show full summary:
Aadi Bioscience: Net Cash, and EU Expansion Could Unlock Upside
AADI: Trading at $1.86, NAV $5.71 ($2.53 net cash + $3.18 FYARRO cash 2025-2028). Potential $7.92 with EU sales. 80% R&D cut, 34 employees left. $24M annual FYARRO sales till 2029 ODD expiry. 206% upside, company for sale. PEComa treatment, BMS licensed, 53-month median survival.
Read full article (3 min)